FDA Grants Priority Review for Giredestrant in Early Breast Cancer Treatment

The FDA has accepted and granted priority review status to a new drug application for giredestrant. This investigational drug aims to treat adult patients with ER-positive, HER2-negative, stage I to III breast cancer. Positive results from a phase 3 trial suggest it could reduce the risk of disease recurrence or death, potentially offering a new standard of care.